Filter By Category
Archives
Share on -
CABOTAMIG
Generic Name: CABOTAMIG
ABSTRACT -
Cabotamig is an investigational bispecific antibody being developed for the treatment of specific haematological or solid tumour cancers. It simultaneously targets a tumour-associated antigen and CD3 on T cells, redirecting cytotoxic T lymphocytes to kill tumour cells. Phase I trials are characterising its safety, tolerability, and anti-tumour activity.
DOSAGE -
Intravenous infusion; flat or weight-based dosing with step-up schedule to mitigate CRS; Q1W or Q2W per clinical protocol.
SIDE EFFECTS-
- Cytokine release syndrome
- Fatigue
- Fever
- Neutropenia
- Elevated liver enzymes
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Infusion hypersensitivity
- Anaphylaxis
- Urticaria
- Angioedema
DRUG INTERACTIONS-
- Avoid live vaccines during treatment
- Additive toxicity with checkpoint inhibitors
- Corticosteroids used for CRS management may reduce T-cell activity
PREAUTONS–
- Hospital-based administration with CRS monitoring for initial doses
- Neurological monitoring for ICANS
- Effective contraception required
- Evaluate infectious disease status pre-treatment
WARNINGS –
- CRS and neurotoxicity can be life-threatening
- Tocilizumab and corticosteroids must be available
- Tumour lysis syndrome risk in high-burden disease
Share on -
. Developed by